OncLive TV

Stuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.

Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

Melissa L. Bondy, PhD, MS, Duncan Cancer Center-Bondy Cancer Prevention and Population Sciences, Baylor College of Medicine, discusses future treatment approaches for patients with glioma.

Manish A. Shah, MD, associate professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Bartlett Family Associate Professor in Gastrointestinal Oncology, medical oncologist, Weill Cornell Medicine and New-York Presbyterian Hospital, discusses the phase IIIb HELOISE trial, which compared 2 dose regimens of trastuzumab combined with chemotherapy as a first-line treatment for patients with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC).

Martine J. Piccart, MD, PhD, professor of Oncology, Université Libre de Bruxelles, director of Medicine, Jules Bordet Institute, Brussels, Belgium, discusses the primary analysis of the prospective randomized MINDACT study, which evaluated the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses critical flaws in the landmark PLCO trial in prostate cancer.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses two studies investigating entrectinib in patients with advanced solid tumors.

Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy.

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.

John P. Leonard, MD, medical oncology, Weill Cornell Medicine and New-York Presbyterian, discusses treatment considerations for relapsed patients with follicular lymphoma.

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses neoadjuvant treatment options for patients with HER2-positive breast cancer.

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.

Jayesh Desai, MD, honorary, Surgery, The Sir Peter MacCallum Department of Oncology, Clinical School-Austin Health, Royal Melbourne Hospital, discusses a phase Ia study exploring BGB-283 in patients with BRAF- or KRAS/NRAS-mutated solid tumors.

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.

Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.

Patricia J. Goldsmith, chief executive officer, CancerCare, previews data of a CancerCare study highlighting some of the financial challenges associated with patients who have cancer.

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.

Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses triplet therapies for patients with melanoma and the sequencing challenges associated with the approvals of additional agents in the field.

Ann H. Partridge, MD, MPH, founder and director, Program for Young Women with Breast Cancer, director, Adult Survivorship Program, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses preimplantation genetic diagnosis (PGD) in young patients with breast cancer.